HDAC6 Inhibitor Platform (Peripheral)
ADPKD, Diabetic Nephropathy, Heart Failure
PreclinicalActive
Key Facts
Indication
ADPKD, Diabetic Nephropathy, Heart Failure
Phase
Preclinical
Status
Active
Company
About Eikonizo Therapeutics
Eikonizo Therapeutics is a private, preclinical-stage biotech focused on selective HDAC6 inhibitors. Its lead CNS candidate, EKZ-102, is in IND-enabling studies for ALS, with plans to expand to other neurodegenerative diseases. The company is also developing peripheral HDAC6 inhibitors for cardiorenal indications like ADPKD and diabetic nephropathy, leveraging a platform designed for high selectivity and CNS penetrance to minimize side effects.
View full company profile